低剂量CT筛查获益的当前证据
低剂量计算机断层扫描(LDCT)筛查可在可治愈阶段诊断肺癌并降低肺癌死亡率,但全球筛查覆盖率仍不理想。本综述汇总支持LDCT筛查的当前证据、各国实施方案及首届AGILE会议要点,涉及风险导向入选标准、人工智能辅助判读、心肺共病评估与多学科路径。
要点
- LDCT筛查可在可治愈分期诊断肺癌并降低肺癌死亡率。
- 通过风险模型扩大入选范围并关注高危从不吸烟与轻度吸烟者,是提高效率与公平性的新兴策略。
- 人工智能辅助判读与影像生物标志物正用于应对假阳性、过度诊断与人力负担问题。
核心结论
- LDCT筛查是降低肺癌死亡率与过早死亡的成本效益机会。
- 为最大化全球影响,筛查策略须针对当地卫生系统与人群进行定制。
研究设计与样本
- 本综述汇总支持LDCT筛查的当前证据、全球实施进展及首届AGILE会议的关键见解。
- 原文未报告检索数据库、检索时间范围与纳入研究数量。
主要发现
- 肺癌仍是全球癌症相关死亡的首位原因,主要归因于晚期诊断。
- LDCT筛查可在可治愈阶段做出诊断并降低肺癌死亡率,但全球摄取率仍不理想。
- 肺癌筛查正获得全球动力,许多国家在推进国家层面LDCT计划。
- 通过风险导向模型扩大入选范围、针对高危从不吸烟与轻度吸烟者,是提高效率与公平性的新兴策略。
- 人工智能辅助判读与影像生物标志物正在应对假阳性、过度诊断与人力负担方面的顾虑;在LDCT筛查中整合心脏与吸烟相关疾病评估可带来额外预防健康获益。
关键数值与推荐
- 原文未报告具体的筛查起始年龄、吸烟暴露阈值、筛查间隔或判读阳性阈值。
临床怎么用
- 筛查策略须针对当地卫生系统与人群进行定制。
- 工作应聚焦于提高认识、标准化方案、优化筛查间隔并强化多学科诊疗路径。
- 国际协作与共享基础设施可加速进展并确保可持续性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lung cancer is the leading cause of cancer-related mortality worldwide, largely due to late-stage diagnosis. Low-dose computed tomography (LDCT) screening has emerged as a powerful tool for early detection, enabling diagnosis at curable stages and reducing lung cancer mortality. Despite strong evidence, LDCT screening uptake remains suboptimal globally. This review synthesizes current evidence supporting LDCT screening, highlights ongoing global implementation efforts, and discusses key insights from the 1st AGILE conference. Lung cancer screening is gaining global momentum, with many countries advancing plans for national LDCT programs. Expanding eligibility through risk-based models and targeting high-risk never- and light-smokers are emerging strategies to improve efficiency and equity. Technological advancements, including AI-assisted interpretation and image-based biomarkers, are addressing concerns around false positives, overdiagnosis, and workforce burden. Integrating cardiac and smoking-related disease assessment within LDCT screening offers added preventive health benefits. To maximize global impact, screening strategies must be tailored to local health systems and populations. Efforts should focus on increasing awareness, standardizing protocols, optimizing screening intervals, and strengthening multidisciplinary care pathways. International collaboration and shared infrastructure can accelerate progress and ensure sustainability. LDCT screening represents a cost-effective opportunity to reduce lung cancer mortality and premature deaths.
引用
- Yip R, Mulshine JL, Oudkerk M, et al. Current evidence of low-dose CT screening benefit. Eur J Cancer. 2025. PMID: 40517528. doi:10.1016/j.ejca.2025.115570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。